Interim Effectiveness of 2025-2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19-Related Outcomes Among Adults Aged ≥ 65 Years in the United States.

IF 5.6 3区医学 Q1 INFECTIOUS DISEASES

Infectious Diseases and Therapy Pub Date : 2026-09-01 Epub Date: 2026-06-24 DOI:10.1007/s40121-026-01395-4

Nevena Vicic, Alina Bogdanov, Heather Hensler, Taylor Ryan, Ni Zeng, Ekkehard Beck, Emily Patry, Machaon Bonafede, Andre B Araujo, Amanda Wilson

{"title":"Interim Effectiveness of 2025-2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19-Related Outcomes Among Adults Aged ≥ 65 Years in the United States.","authors":"Nevena Vicic, Alina Bogdanov, Heather Hensler, Taylor Ryan, Ni Zeng, Ekkehard Beck, Emily Patry, Machaon Bonafede, Andre B Araujo, Amanda Wilson","doi":"10.1007/s40121-026-01395-4","DOIUrl":null,"url":null,"abstract":"Introduction: The 2025-2026 COVID-19 vaccine season introduced updated formulations targeting the LP.8.1 lineage. This interim analysis assessed absolute vaccine effectiveness (aVE) of mRNA-1283 and BNT162b2 on COVID-19 outcomes in adults aged ≥ 65 years.Methods: This retrospective study used linked electronic health record and administrative claims data through January 31, 2026. Adults ≥ 65 years who received the mRNA-1283 or BNT162b2 2025-2026 COVID-19 vaccine were matched to unvaccinated individuals. Inverse probability of treatment weighting was applied to each vaccine's matched cohorts to balance covariates. Each vaccine was evaluated independently against its own unvaccinated comparator group. aVE against COVID-19-related hospitalization and medically attended COVID-19 was estimated using Cox proportional hazards models; aVE = 100 × (1 - hazard ratio).Results: We identified 233,072 mRNA-1283 recipients and 422,610 BNT162b2 recipients ≥ 65 years. aVE (95% confidence interval [CI]) of mRNA-1283 against COVID-19-related hospitalization and medically attended COVID-19 was 59.3% (39.0%, 72.9%) and 42.0% (35.0%, 48.3%) among adults ≥ 65 years and 66.9% (45.9%, 79.8%) and 50.2% (42.1%, 57.2%) in ≥ 75 years, respectively. The aVE (95% CI) of BNT162b2 against COVID-19-related hospitalization and medically attended COVID-19 was 48.3% (32.4%, 60.5%) and 41.2% (36.2%, 45.8%) in ≥ 65 years and 45.9% (26.0%, 60.4%) and 44.0% (37.8%, 49.6%) in ≥ 75 years, respectively.Conclusion: This study provides the first real-world evidence that mRNA-1283 was associated with protection against COVID-19-related hospitalization and medically attended COVID-19 among vulnerable older adults at highest risk of severe disease. These findings support mRNA-1283 as an important public health tool for reducing the continual burden of COVID-19 in this population.","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":"2307-2318"},"PeriodicalIF":5.6000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13476419/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-026-01395-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/24 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The 2025-2026 COVID-19 vaccine season introduced updated formulations targeting the LP.8.1 lineage. This interim analysis assessed absolute vaccine effectiveness (aVE) of mRNA-1283 and BNT162b2 on COVID-19 outcomes in adults aged ≥ 65 years.

Methods: This retrospective study used linked electronic health record and administrative claims data through January 31, 2026. Adults ≥ 65 years who received the mRNA-1283 or BNT162b2 2025-2026 COVID-19 vaccine were matched to unvaccinated individuals. Inverse probability of treatment weighting was applied to each vaccine's matched cohorts to balance covariates. Each vaccine was evaluated independently against its own unvaccinated comparator group. aVE against COVID-19-related hospitalization and medically attended COVID-19 was estimated using Cox proportional hazards models; aVE = 100 × (1 - hazard ratio).

Results: We identified 233,072 mRNA-1283 recipients and 422,610 BNT162b2 recipients ≥ 65 years. aVE (95% confidence interval [CI]) of mRNA-1283 against COVID-19-related hospitalization and medically attended COVID-19 was 59.3% (39.0%, 72.9%) and 42.0% (35.0%, 48.3%) among adults ≥ 65 years and 66.9% (45.9%, 79.8%) and 50.2% (42.1%, 57.2%) in ≥ 75 years, respectively. The aVE (95% CI) of BNT162b2 against COVID-19-related hospitalization and medically attended COVID-19 was 48.3% (32.4%, 60.5%) and 41.2% (36.2%, 45.8%) in ≥ 65 years and 45.9% (26.0%, 60.4%) and 44.0% (37.8%, 49.6%) in ≥ 75 years, respectively.

Conclusion: This study provides the first real-world evidence that mRNA-1283 was associated with protection against COVID-19-related hospitalization and medically attended COVID-19 among vulnerable older adults at highest risk of severe disease. These findings support mRNA-1283 as an important public health tool for reducing the continual burden of COVID-19 in this population.

查看原文本刊更多论文

2025-2026 mRNA-1283和BNT162b2 COVID-19疫苗在美国65岁以上成年人中对COVID-19相关结果的中期有效性

2025-2026年COVID-19疫苗季推出了针对LP.8.1谱系的更新配方。该中期分析评估了mRNA-1283和BNT162b2对≥65岁成人COVID-19结局的绝对疫苗有效性（aVE）。方法：本回顾性研究使用截至2026年1月31日的相关电子健康记录和行政索赔数据。接受mRNA-1283或BNT162b2 2025-2026 COVID-19疫苗的≥65岁成人与未接种疫苗的个体进行匹配。将治疗加权的逆概率应用于每个疫苗匹配的队列以平衡协变量。每种疫苗与未接种的比较组进行独立评估。使用Cox比例风险模型估计与COVID-19相关的住院和就医COVID-19的aVE；aVE = 100 ×（1 -风险比）。结果：年龄≥65岁的mRNA-1283受体为233,072例，BNT162b2受体为422,610例。在≥65岁的成年人中，mRNA-1283对COVID-19相关住院和就诊的aVE（95%可信区间[CI]）分别为59.3%（39.0%,72.9%）和42.0%(35.0%,48.3%)，在≥75岁的成年人中分别为66.9%（45.9%,79.8%）和50.2%（42.1%,57.2%）。≥65岁时BNT162b2对COVID-19相关住院和就诊的aVE （95% CI）分别为48.3%（32.4%,60.5%）和41.2%(36.2%,45.8%)，≥75岁时分别为45.9%（26.0%,60.4%）和44.0%（37.8%,49.6%）。结论：本研究提供了第一个真实世界的证据，证明mRNA-1283与严重疾病风险最高的弱势老年人对COVID-19相关住院和就医的保护有关。这些发现支持mRNA-1283作为减少这一人群中COVID-19持续负担的重要公共卫生工具。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Diseases and Therapy Medicine-Microbiology (medical)

CiteScore

8.60

自引率

1.90%

发文量

136

审稿时长

6 weeks

期刊介绍： Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.